SYRS - Syros Pharmaceuticals

-

$undefined

N/A

(N/A)

Syros Pharmaceuticals OTC Markets OTCPK:SYRS Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Location: 35 CambridgePark Drive, Cambridge, MA, 02140, United States | Website: https://www.syros.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.777M

Cash

58.28M

Avg Qtr Burn

-25.0M

Short % of Float

3.52%

Insider Ownership

0.76%

Institutional Own.

16.37%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

SM-88 Details
Bone cancer, Sarcoma

Failed

Discontinued

SM-88 Details
Sarcoma, Bone cancer, Breast cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Tamibarotene (SY-1425) (RARα agonist) Details
Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Failed

Discontinued

Failed

Discontinued

SM-88 Details
Prostate cancer, Prostate disease

Failed

Discontinued

SM-88 Details
Pancreatic cancer

Failed

Discontinued